Comparative analysis of leading pharmacopoeias requirements for the quality of heterologous serum products

The article is devoted to a comparative analysis of requirements to the heterologous serum products stipulated in the world leading Pharmacopoeias: the US Pharmacopoeia, the European Pharmacopoeia, the British Pharmacopoeia, the Japanese Pharmacopoeia and the State Pharmacopoeia of the Russian Federation. It was revealed that the range of antibacterial and antiviral heterologous serum products manufactured in the USA, Europe and Japan differs from that manufactured in Russia. Prevention and treatment of some infectious diseases abroad is mainly achieved with the help of human immunoglobulins, while the prevention of other infections, such as anthrax, is only achieved by vaccination. Nevertheless, heterologous serum products are still used in clinical practice all over the world. The range of such products is the same in all countries. Some of these products are included into the WHO Essential Medicines List. The results of the analysis demonstrate that Russian antitoxic serum products are not inferior to foreign analogues in terms of safety and efficacy. A more detailed characterization of Russian products could help harmonize requirements of Russian and foreign pharmacopoeias to these products and help Russian products enter the foreign market.

гипериммунные сыворотки, гетерологичные иммуноглобулины, антитоксические сыворотки, антивеном, фармакопея, гармонизация, специфическая активность, hyperimmune serum, heterologous immunoglobulins, antitoxic serum, antisera, antivenom, pharmacopoeia, harmonization, specific activity

1. Vasil’ev AN, Gavrishina EV, Nijazov RR, Snegireva AA, Adonin VK. Introduction to European Law. Remedium 2013; September: 49–54 (in Russian).

2. European Pharmacopoeia 9.0; 2017. Available from: http://online6.edqm.eu/ep900.

3. The Eurasian Economic Commission [official site]. Available from: https://goo.gl/XRVXN5.

4. The State Pharmacopoeia of the Russian Federation. 13th edition. V. 1, 2, 3. Moscow; 2015. Available from: http://www.femb.ru/ feml (in Russian).

5. Supotnitsky MV, Elapov AA, Borisevich IV, Kudasheva EYu, Klimov VI, Lebedinskaya EV, et al. Blood preparations of humans and animals in terms of their quality, efficacy and safety. Biopreparations. Prevention, Diagnosis, Treatment 2015; (3): 33–48 (in Russian).

6. Clinical Trials. A service of the U. S. National Institutes of Health [îôèöèàëüíûé ñàéò]. Available from: https://goo.gl/UHcqNz.

7. Dart RC, Seifert SA, Boyer LV, Clark RF, Hall E, McKinney P, et al. A randomized multicenter trial of crotalinae polyvalent immune Fab (ovine) antivenom for the treatment for crotaline snakebite in the United States. Arch Intern Med. 2001; 161(16): 2030–6.

8. Model Lists of Essential Medicines. WHO. Available from: https://goo.gl/JyoKi4.

9. Essential medicines. WHO. Available from: https://goo.gl/lMj0jq.

10. Both L, White J, Mandal S, Efstratiou A. Access to diphtheria antitoxin for therapy and diagnostics. Euro Surveill. 2014; 19(24) pii: 20830. Available from: https://goo.gl/ZsDVuY.

11. State Register of Medicines. Russian Federation Ministry of Health [official site]. Available from: http://grls.rosminzdrav.ru (in Russian).

12. Komissarov AV, Komosko GV, Leshchenko AA, Lub MYu, Pimenov EV, Darmov IV, et al. The sterilizing filtration of horse anti-anthrax liquid globulin preparation. Biotechnologiya 2002; (2): 66–74 (in Russian).

13. Shevtsov AN, Borisevich IV, Darmov IV, Kozhukhov VV, Lub MYu, Kozlova TN, et al. Serum immunobiological preparation for prophylaxis and therapy of anthrax. Biotechnologiya 2011; (1): 42–6 (in Russian).

14. Khmelev AL, Borisevich IV, Pantyukhov VB, Pirozhkov AP, Syromyatnikova SI, Shatokhina IV, et al. Use of guinea pigs to evaluate the efficacy of a heterological immunoglobulin against Bolivian hemorrhagic fever. Voprosy virusologii 2009; 54(4): 42–4 (in Russian).

15. Borisevich IV, Potryvayeva NV, Melnikov SA, Yevseyev AA, Krasnyansky VP, Maksimov VA. Design of equine serum-based Marburg virus immunoglobulin. Voprosy virusologii 2008; 53(1): 39–41 (in Russian).

16. Mikhaylov VV, Borisevich IV, Timankova GD, Krasnyansky VP, Potryvaeva NV, Lebedinskaya EV, Chernikova NK. The preparation containing immunoglobulin against Ebola fever from horse blood serum liquid (immunoglobulin Ebola). Patent RUS 2130318 C1; 1996 (in Russian).

17. Borisevich IV, Mikhaylov VV, Khamitov RA, Krasnyansky VP, Chernikova NK, Evseev AA, Mironov AN. Use of monkeys for the preclinical evaluation of specific means of prevention and treatment of hemorrhagic fevers Ebola and Lassa. In: Organisms and environment: Human livelihoods protection in extreme conditions. Mater. Ross. Konf. 2000. P. 210 (in Russian).

18. Krasnyansky VP, Gradoboev VN, Borisevich IV, Potryvaeva NV, Lebedinskaya EV, Chernikova NK, Timankova GD. Development and study of the properties of immunoglobulin against Lassa fever. Voprosy virusologii 1997; 42(4): 168–71 (in Russian).

19. Khmelev AL, Borisevich IV, Chernikova NK, Makhlay AA, Mikhaylov VV, Yakovlev AK, at al. Evaluation of safety of prophylactic use of immunoglobulins against viral hemorrhagic fevers from horse blood sera. Zhurnal mikrobiologii, epidemiologii, immunobiologii 2012; (6): 103–6 (in Russian).

20. Krasnyansky VP, Mikhaylov VV, Lukin EP, Borisevich IV, Potryvaeva NV, Melnikov SA, et al. The preparation containing immunoglobulin against VEE from horse blood serum liquid (immunoglobulin against VEE from horse blood serum). Patent RUS 2261113 C1 2003 (in Russian).

21. British Pharmacopoeia 2009. Medicines and Healthcare product Regulatory Agency (MHRA) [GB] [official site]. Available from: https://www.pharmacopoeia.com.

22. The Japanese Pharmacopoeia, 15th ed. Available from: http://gmpua.com/Pharmacopeia/index.html.

23. U. S. Pharmacopeial Convention [official site]. Available from: http://www.usp.org.

24. U. S. Food &Drug Administration. U. S. Department of Health and Human Services [official site]. Available from: https://goo.gl/ OSQjAP.

25. U. S. Food &Drug Administration. U. S. Department of Health and Human Services [official site]. Available from: https://goo.gl/ 6Fd7S4.

26. U. S. Food &Drug Administration. U. S. Department of Health and Human Services [official site]. Available from: https://goo.gl/ ePGHji.

27. U. S. Food &Drug Administration. U. S. Department of Health and Human Services [official site]. Available from: https://goo.gl/ oiR4Hk.

28. U. S. Food &Drug Administration. U. S. Department of Health and Human Services [official site]. Available from: https://goo.gl/ RtCfS2.

29. U. S. Food &Drug Administration. U. S. Department of Health and Human Services [official site]. Available from: https://goo.gl/ NbKl6m.

30. The Bioclon Institute S. A. de C. V., Maxico [îôèöèàëüíûé ñàéò]. Available from: http://www.bioclon.com.mx.

31. Paniagua-Solis JF, Mancilla R, Gonzalez C, Alagón A. From serotherapy to fabotherapy. J Venom Anim Toxins. 2001; 7(2) Available from: http://dx.doi.org/10.1590/S0104-79302001000200036.

32. Sotelo N. Review of treatment and complications in 79 children with rattlesnake bite. Clin Pediatr (Phila). 2008; 47(5): 483–9.

33. Darracq MA, Cantrell FL, Klauk B, Thornton SL. A chance to cut is not always a chance to cure-fasciotomy in the treatment of rattlesnake envenomation: A retrospective poison center study. Toxicon. 2015; 101: 23–6.

34. Vazquez H, Chavez-Haro A, Garcýa-Ubbelohde W, Mancilla-Nava R, Paniagua-Solýs J, Alagon A, Sevcik C. Pharmacokinetics of a F(ab)2 scorpion antivenom in healthy human volunteers. Toxicon 2005; 46: 797–805.

35. Borisevich IV, Kudasheva EYu, Perelygina OV, Mironov AN, Merkulov VA, Bondarev VP et al. State of the problem of standardization of specific immunoglobulins and antitoxic sera. Meditsinskaya immunologiya 2015; 17(5): 379 (in Russian).

36. Bondarev VP, Kargina TM, Sakanjan EI. On assessment of the quality of preservatives used in modern practice production of immunobiological drugs. Vedomosti Scientific Centre of Expertise of Medical application. 2015; (1): 53–8 (in Russian).

37. Alekseeva IA, Chuprynina RP, Perelygina OV, Mironov AN. Harmonisation of requirements for the DPT vaccine in the project FA Vaccine Pertussis-DiphtheriaTetanus Toxoids Adsorbed. Biopreparations. Prevention, Diagnosis, Treatment 2013; (1): 36–9 (in Russian).

38. Kolbin AS. On the quastion of adverse reactions to administrating biological medicines. Vedomosti Nauchnogo tsentra ekspertisy sredstv meditsinskogo primeneniya 2013; (3): 29–32 (in Russian).